‘Mass Spectrometry Market Worth Over $3.8 Billion In 2017’ Says Visiongain Report

28 August 2017
Pharma

Visiongain’s new report The Mass Spectrometry Market Forecast 2017-2027 – Revenue Prospects by Technology (Single, Ion Trap, Quadrupole, TOF, Hybrid, Triple Quadrupole, Q-TOF, FTMS), by Application (Academia, Biotech, Agriculture, CRO, Hospitals, Environmental, Materials) and Geography indicates that the global mass spectrometry market will see over $3.8bn in revenue in 2017.

The lead analyst of the report said:

“The mass spectrometry market is expected to experience considerable growth over the forecast period. The main drivers for the growth include the applications of the mass spectrometry in wide range of areas, technological advancements and adoption/acceptability of new technology by the government to address the healthcare challenges. The increasing disease burden and identification of antibacterial resistant strains is leading to therapeutical advancements, drug discovery and increase research and development activities to address this situation. The high-speed, accurate, sample analysis of simple to complex molecules/products by the mass spectrometry is leading to its increased demand in the areas such as clinical research, proteomic, metabolomics, and forensics including many others.”
The 183-page report contains 111 tables, charts and graphs that add visual analysis in order to explain developing trends within the mass spectrometry market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading mass spectrometry submarkets, segmented by technology, with forecasts for single and hybrid mass spectrometry. The market is also segmented by product, and includes forecasts for Ion Trap, Quadrupole, TOF, Triple Quadrupole, Quadrupole-TOF and Fourier Transform Mass Spectrometry. The report also includes forecasts for the applications of mass spectrometry, including academic, biotech, agriculture, contract research, hospital, environmental and material usage.

The 183-page report offers market forecasts and analysis for 4 regional and 12 national markets. In addition, the report contains a dedicated leading companies’ chapter covering 10 companies leading the field in mass spectrometry technology.

The Mass Spectrometry Market Forecast 2017-2027 – Revenue Prospects by Technology (Single, Ion Trap, Quadrupole, TOF, Hybrid, Triple Quadrupole, Q-TOF, FTMS), by Application (Academia, Biotech, Agriculture, CRO, Hospitals, Environmental, Materials) and Geography report will be of value to anyone who wants to better understand the mass spectrometry market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the mass spectrometry industry.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read